Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Breast Adenocarcinoma|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7
Interventions: DRUG: Neratinib|BIOLOGICAL: Trastuzumab|DRUG: Loperamide|DRUG: Diphenoxylate Hydrochloride/Atropine Sulfate
Sponsor: University of California, San Francisco
Collaborators: Puma Biotechnology, Inc.